Iridex Stock Price, News & Analysis

Iridex Corporation (Nasdaq: IRIX) reported a remarkable 116% year-over-year revenue growth for Q2 2021, reaching $13.4 million, the highest since 2007. Gross profit also soared to $6.1 million with a 45.5% gross margin. The company achieved record sales of Cyclo G6 probes, totaling 16,000 units, a 103% increase from last year. Net income turned positive at $1.4 million, compared to a net loss of $2.8 million a year ago. Iridex updated its full year 2021 revenue guidance to $50 million - $52 million, indicating a growth of 38% - 43% compared to 2020.

IRIDEX Corporation (Nasdaq: IRIX) has announced its participation in the upcoming H.C. Wainwright Ophthalmology Virtual Conference set for August 17, 2021. The company specializes in innovative ophthalmic laser-based medical products aimed at treating conditions such as glaucoma and retinal diseases. David Bruce, the President and CEO, is scheduled to present at 7:00 am ET. Interested parties can access the live and archived webcast through iridex.com.

The company is recognized for its MicroPulse® technology, enhancing treatments for eye conditions worldwide.

Iridex Corporation (NASDAQ: IRIX), based in Mountain View, California, plans to release its financial results for Q2 2021 on August 12, 2021, after market close. The management team will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results. Investors can join the call by dialing (844) 707-0665 domestically or (703) 326-3030 internationally, using conference ID: 9257308. A live and archived webcast will also be available on Iridex's website.

Iridex Corporation (Nasdaq: IRIX) reported strong financial results for Q1 2021, achieving record revenue of $12.0 million, up 33% from $9.0 million year-over-year. The growth was driven by a strategic collaboration with Topcon, contributing $19.5 million in funds and robust sales of new products. Cyclo G6 product sales reached $3.3 million, marking a 15% increase. Despite a net loss of $2.0 million, the company holds $28 million in cash, expecting full-year revenue of $48 million to $51 million, representing growth of 32%-40%.

Iridex Corporation (NASDAQ: IRIX) announced that it will release its financial results for Q1 2021 on May 11, 2021, after trading hours. A conference call will follow at 2:00 p.m. PT / 5:00 p.m. ET. The call can be accessed by domestic callers at (844) 707-0665 and international callers at (703) 326-3030, using conference ID: 1282162. Iridex specializes in innovative ophthalmic laser-based medical products for glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology to deliver effective treatments worldwide.

Iridex Corporation (Nasdaq: IRIX) reported a 5% increase in fourth-quarter revenue to $12.3 million year-over-year, driven by an 8% growth in U.S. Cyclo G6 probe sales. Gross margin improved to 45.4%, aided by higher selling prices and reduced operating expenses, which fell by 9% to $5.9 million. The company experienced a reduced net loss of $179,000. For 2020, total revenue decreased to $36.3 million due to COVID-19 impacts, while the net loss was cut to $6.3 million. Guidance for 2021 remains uncertain due to ongoing COVID challenges and the new collaboration with Topcon Corporation.

Iridex Corporation (NASDAQ: IRIX) announced the completion of a significant transaction with Topcon Corporation, involving a $10 million equity investment and exclusive distribution rights for its products in key regions. The total deal nets Iridex $19.5 million, providing capital for strategic growth in glaucoma and retina product lines. CEO David Bruce highlighted the partnership's potential to enhance global patient care and physician support. The transaction was initially revealed on March 2, 2021.

Iridex Corporation (NASDAQ: IRIX) will release its financial results for Q4 and full year 2020 after trading on March 22, 2021. A conference call with management is scheduled for 2:00 p.m. PT / 5:00 p.m. ET, which investors can access by calling (844) 707-0665 domestically or (703) 326-3030 internationally, using conference ID: 1137827. The event will also be webcast live and archived on Iridex's website. The company specializes in ophthalmic laser-based medical products for glaucoma and retinal diseases.

Iridex (NASDAQ: IRIX) announced a strategic collaboration with Topcon Corporation, securing $19.5 million in cash to fuel growth in glaucoma and retinal disease treatments. This partnership includes exclusive distribution rights for Iridex's products in key markets and a 10.4% equity stake acquisition by Topcon. Iridex will also gain the PASCAL® product line from Topcon, enhancing its portfolio. The collaboration aims to improve market penetration and operational efficiencies. A conference call is scheduled for March 2, 2021, to discuss the partnership further.